C
Chengdu Usano Biotechnology
Allogeneic universal CAR-T cell therapeutic drug development
About Chengdu Usano Biotechnology
Chengdu Usano Biotechnology, also known as Ucello Therapeutics, is a biotechnology company established in 2020 with headquarters in Chengdu, Sichuan, China. The firm concentrates on the research and development of allogeneic universal CAR-T cell therapy drugs. Ucello's proprietary CBT-X20 technology platform utilizes lentiviral infection of T-cells, gene editing, in-vitro cultivation, expansion, and cryopreservation techniques. This platform aims to create "off-the-shelf" cell therapies for treating solid tumors and hematologic malignancies. A key product, UC101, is noted as the first FDA IND-approved allogeneic CAR-T therapy derived from umbilical cord blood.
The company's approach to manufacturing employs a stable producer cell line for the lentiviral vector, which avoids the need for plasmid DNA and is designed to lower production costs and improve consistency between batches. By using umbilical cord blood, a single batch can potentially be sufficient to treat over 100 patients, enhancing the accessibility of CAR-T therapy. Ucello operates on a B2B model within the biotech and pharmaceutical industry, developing therapies that target cancer cells at a molecular level. This allows treatment for patients who may have previously been ineligible for such therapies due to lymphocyte levels or transplant relapse history.
In February 2022, Ucello Therapeutics secured US$25 million in a Series A funding round. The round was led by Matrix Partners China and included participation from Co-Win Ventures, Northern Light Venture Capital, and Elikon Venture. The stated purpose of the funding was to advance the development of its universal CAR-T technology platform, progress its pipeline programs, and establish GMP-ready clinical manufacturing facilities. The company is led by CEO Dr. Qiang Zou.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2023 | $21M | $125M | Matrix Partners China · Cowin Venture · Shenzhen Guozhong Venture Capital Management · Juke Investment | ↗ |
| SERIES A✓Equity / VC | Feb 2022 | $25M | $100M | Elikon Venture · NLVC · Chengdu Bio-town Fund · Cowin Venture | ↗ |
Growth signals
Latest recorded traffic for Chengdu Usano Biotechnology is 120 monthly website visits, down 91.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chengdu Usano Biotechnology in the Chengdu ecosystem
The Chengdu Usano Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Matrix Partners China- EVElikon Venture
NLVC- CFChengdu Bio-town Fund
Cowin Venture
Shenzhen Guozhong Venture Capital Management- JIJuke Investment
- GCGuosheng Capital
- PCPenglai Capital
Other known investors1 additional known investor
Chengdu Medical College
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chengdu Usano Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chengdu Usano Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










